Transplantation Using Haploidentical Donors Outperforms Matched Sibling Donors in MRD+ ALL
September 9th 2020Haploidentical donor transplantation led to stronger anti-leukemia activity compared with matched sibling donor transplantation in transplant-eligible patients with minimal residual disease–positive acute lymphoblastic leukemia.
Read More
Basiliximab Elicits High Response Rates After Haploidentical HSCT in Pediatric Acute GVHD
September 8th 2020Basiliximab proved to be an effective second-line treatment option for pediatric patients with steroid-refractory acute graft-versus-host disease that developed following haploidentical hematopoietic stem cell transplantation.
Read More
Pembrolizumab Benefit Not Altered by KRAS Status in Nonsquamous NSCLC
January 7th 2020Two analyses presented at the 2019 ESMO Immuno-Oncology Congress provided data supporting pembrolizumab, either as monotherapy or in combination with chemotherapy, as a first-line treatment option in patients with nonsquamous non–small cell lung cancer, regardless of KRAS mutational status.
Read More
Safety of Frontline Durvalumab Combo Confirmed in Extensive-Stage Small Cell Lung Cancer
January 4th 2020Few immune-mediated adverse events were observed with frontline durvalumab plus platinum-based therapy and etoposide in patients with extensive-stage small cell lung cancer, and no treatment-emergent antidrug antibodies were elicited by the PD-L1 inhibitor, according to an analysis of the phase III CASPIAN trial reported at the 2019 ESMO Immuno-Oncology Congress.
Read More
Frontline Nivolumab/Ipilimumab Shows Clinical Benefit in NSCLC With Poor Prognosis
January 4th 2020First-line treatment with nivolumab combined with low-dose ipilimumab was safe and showed encouraging overall survival, regardless of PD-L1 expression, in patients with advanced non–small cell lung cancer, including those with comorbidities or poor ECOG performance status.
Read More
BL-8040 Plus Pembrolizumab/Chemo Provides Disease Control in Pancreatic Cancer
January 2nd 2020A triplet regimen of the CXCR4 antagonist BL-8040 plus pembrolizumab and standard chemotherapy showed promising antitumor activity in the second-line setting for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
Read More
The first-line combination of nivolumab and platinum-based chemotherapy improved overall survival, progression-free survival, and objective response rate compared with chemotherapy in patients with squamous non–small cell lung cancer, but did not improve survival in those with nonsquamous disease.
Read More
High PD-L1 Expression, bTMB Effective Markers for Single-Agent Atezolizumab Benefit in NSCLC
December 29th 2019PD-L1-high status, determined via 3 separate immunohistochemistry assays, and blood tumor mutational burden strongly favored atezolizumab over platinum-based chemotherapy and supports the PD-L1 inhibitor as a first-line treatment option in patients with advanced non–small cell lung cancer.
Read More
Concurrent Ibrutinib With CAR T-Cell Therapy Improves ORR, Reduces Severe CRS in High-Risk CLL
June 22nd 2019Patients with high-risk relapsed/refractory chronic lymphocytic leukemia who failed or were intolerant of ibrutinib derived more benefit from CD19‐targeted CAR T-cell therapy when the BTK inhibitor was concurrently administered than when it was not.
Read More
Lisocabtagene Maraleucel Continues to Show Promise in Relapsed/Refractory CLL
June 21st 2019The CAR T-cell therapy lisocabtagene maraleucel demonstrated high rates of response, including minimum residual disease in blood and marrow in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Genetic Analysis Provides Insight Into Venetoclax/Obinutuzumab Benefit in Frontline CLL
June 20th 2019In a careful evaluation of chemotherapy‐free regimens, the combination of obinutuzumab plus venetoclax compared to obinutuzumab plus chlorambucil, objective and complete response rates, as well as progression-free survival were superior with the venetoclax combination in the overall study population and across all genetic subgroups evaluated in patients with chronic lymphocytic lymphoma.
Read More
Optimal Upfront Lenalidomide/R-CHOP Use Remains Puzzle in DLBCL
June 20th 2019Patients with activated B-cell-type diffuse large B-cell lymphoma with a poor prognosis may benefit from frontline treatment with lenalidomide plus standard R-CHOP, according to subgroup data from the phase III ROBUST trial presented at the 2019 International Conference on Malignant Lymphoma.
Read More
Single-Agent Acalabrutinib Showcases Potential Practice-Changing Data in Relapsed/Refractory CLL
June 17th 2019Chemotherapy-free treatment with single-agent acalabrutinib provided a statistically significant and clinically meaningful improvement in progression-free survival compared with physicians’ choice of standard therapy in patients with previously treated chronic lymphocytic leukemia.
Read More
Phase III BELLINI Data Showcase Safety Concerns With Venetoclax in Multiple Myeloma
June 16th 2019Despite promising progression-free survival and response data with venetoclax in combination with bortezomib and dexamethasone, an increased number of deaths due to infection in the experimental arm marred overall survival findings in patients with relapsed/refractory multiple myeloma.
Read More
New Macrophage Immune Checkpoint Strategy Shows Promise in AML and MDS
June 16th 2019Hu5F9-G4 (5F9), a first-in-class antibody targeting CD47, used as monotherapy or in combination with standard azacitidine was well tolerated and provided deep and durable responses in patients with acute myeloid leukemia or myelodysplastic syndrome, according to findings from a phase IB study presented at the 2019 European Hematology Association Congress.
Read More
Addition of Rigosertib Improves Azacitidine Benefit in Patients With Higher-Risk MDS
June 15th 2019The combination of rigosertib and azacitidine demonstrated improved response rates over single-agent azacitidine in patients with higher-risk myelodysplastic syndrome, including patients naïve to a hypomethylating (HMA) agent and those who were refractory to HMAs.
Read More
Frontline Ibrutinib Showcases Long-Term OS Benefit in Older Patients With CLL
June 15th 2019Frontline therapy with ibrutinib was successfully administered for more than 60 months in patients with chronic lymphocytic leukemia aged 65 years and older and provided improved progression-free and overall survival compared with chlorambucil.
Read More
Atezolizumab Regimen Improves OS After TKI Failure in EGFR+ NSCLC
April 14th 2019Atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with EGFR-positive metastatic nonsquamous non–small cell lung cancer who have failed prior TKIs.
Read More
Nivolumab/Ipilimumab Falls Short as Maintenance Therapy in SCLC
April 13th 2019No overall survival advantage was obtained from maintenance therapy comprising nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) over placebo in patients with extensive-stage small cell lung cancer.
Read More
Update Further Supports Osimertinib in Frontline EGFR+ NSCLC
April 12th 2019Final results from 2 phase I expansion cohorts of frontline osimertinib (Tagrisso) presented at the 2019 European Lung Cancer Congress confirmed the efficacy of the third-generation TKI in patients with EGFR-positive non­–small cell lung cancer.
Read More
PD-L1 Expression Does Not Impact QoL With Durvalumab in NSCLC
April 11th 2019Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study.
Read More
Subsequent Immunotherapy in Control Arm Confounds Frontline Durvalumab Data in NSCLC
April 11th 2019The initial overall survival analysis of the phase III MYSTIC trial of first-line durvalumab (Imfinzi) alone or in combination with tremelimumab compared with platinum-based chemotherapy in patients with metastatic non–small cell lung cancer, may have been confounded by high rates of post-study immunotherapy given in the control arm.
Read More